Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Abstract Introduction This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Methods Eligible patients who had receiv...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua: Rebecca Dent, Geoffrey J. Lindeman, Mark Clemons, Hans Wildiers, Arlene Chan, Nicole McCarthy, Christian F. Singer, Elizabeth Lowe, Claire Watkins, James Carmichael
Hōputu: Artigo
Reo:Ingarihi
I whakaputaina: 2013
Urunga tuihono:https://doi.org/10.1186/bcr3484
https://breast-cancer-research.biomedcentral.com/counter/pdf/10.1186/bcr3484
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ipurangi

https://doi.org/10.1186/bcr3484
https://breast-cancer-research.biomedcentral.com/counter/pdf/10.1186/bcr3484

Ngā tūemi rite